Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) Director Jan Johannessen sold 12,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total value of $673,440.00. Following the completion of the transaction, the director directly owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. This trade represents a 40.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Twist Bioscience Stock Performance
TWST stock traded down $1.44 during midday trading on Thursday, hitting $52.95. The stock had a trading volume of 912,978 shares, compared to its average volume of 1,333,233. The firm has a market capitalization of $3.30 billion, a price-to-earnings ratio of -39.81 and a beta of 2.22. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $66.06. The stock has a 50-day simple moving average of $51.70 and a 200 day simple moving average of $42.32. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period last year, the business earned ($0.66) earnings per share. As a group, equities research analysts anticipate that Twist Bioscience Corporation will post -1.86 earnings per share for the current year.
Institutional Trading of Twist Bioscience
Analyst Ratings Changes
TWST has been the subject of a number of analyst reports. Evercore lifted their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Robert W. Baird lifted their price objective on Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Guggenheim lifted their price objective on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Leerink Partners raised Twist Bioscience from a “market perform” rating to an “outperform” rating and set a $70.00 price objective for the company in a report on Tuesday, May 5th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $56.57.
Get Our Latest Research Report on TWST
Twist Bioscience Company Profile
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
- Five stocks we like better than Twist Bioscience
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
